Target intelligence / Profile preview

NADH:ubiquinone oxidoreductase (Complex I) ubiquinone-binding site (Complex I Q-site)

Target
Complex I Q-site
Molecular classification
Enzyme, Oxidoreductase, Mitochondrial respiratory chain complex
01

Overview

Mitochondrial Complex I (NADH:ubiquinone oxidoreductase) is the largest enzyme of the mitochondrial respiratory chain, playing a central role in cellular energy production (Source: UniProt). The Q-binding site is a narrow, hydrophobic tunnel where ubiquinone (Coenzyme Q10) is reduced to ubiquinol, a process coupled to the pumping of four protons across the inner mitochondrial membrane to drive ATP synthesis (Source: PubMed, PMID: 32555455). This site is a significant pharmacological target; for instance, the anti-diabetic drug metformin is known to inhibit Complex I at this site to activate the AMPK pathway and reduce hepatic glucose production (Source: NIH, StatPearls). However, dysfunction or potent inhibition of the Q-binding site by substances like rotenone is linked to increased reactive oxygen species (ROS) production and neurodegenerative conditions such as Parkinson's disease (Source: Wikipedia, "Complex I"). Mutations in the subunits forming this site are also associated with mitochondrial diseases like Leber's hereditary optic neuropathy (Source: MedlinePlus). Understanding the structural dynamics of this site is crucial for developing new therapeutics that can modulate mitochondrial function without inducing systemic toxicity.

Other names
NADH dehydrogenase (ubiquinone) Q-binding siteComplex I quinone-binding pocketUbiquinone-binding site of Complex IMitochondrial Complex I Q-binding site
02

Mechanism of action

Inhibition of electron transfer from the terminal iron-sulfur cluster (N2) to ubiquinone within the hydrophobic pocket, which reduces the proton motive force and can trigger secondary signaling pathways like AMPK activation (Source: PubMed, PMID: 25190156).

03

Biological functions

Oxidative phosphorylationElectron transport chainATP synthesisReactive oxygen species (ROS) generationProton translocation
04

Disease associations

Type 2 diabetesParkinson's diseaseMitochondrial encephalomyopathyCancerLeber's hereditary optic neuropathy (LHON)
05

Safety considerations

Lactic acidosisMitochondrial toxicityNeurotoxicityIncreased oxidative stress
06

Interacting drugs

Metformin

6 more in the full profile.

07

Biomarkers

Lactate/pyruvate ratioOxygen consumption rate (OCR)AMPK phosphorylationMitochondrial membrane potential

Beyond the preview

Go deeper on NADH:ubiquinone oxidoreductase (Complex I) ubiquinone-binding site (Complex I Q-site).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH:ubiquinone oxidoreductase (Complex I) ubiquinone-binding site (Complex I Q-site).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call